文献速递糖尿病性腺与生殖内分泌

激素避孕与糖尿病女性血栓栓塞风险

Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes.
PubMed 文献 · Diabetes Care · 2016-11-29

基于美国2002-2011年Clinformatics Data Mart数据,纳入14-44岁且有糖尿病用药或器械处方的1型或2型糖尿病女性146,080例,共发生3,012例血栓栓塞事件,采用改良Cox回归分析不同激素避孕方式至血栓栓塞的时间。使用激素避孕的糖尿病女性绝对血栓栓塞风险较低,宫内与皮下埋植避孕药具是希望避免高血糖致畸效应、认真计划妊娠的糖尿病女性的优良选择。

要点

  • 使用激素避孕的1型或2型糖尿病女性血栓栓塞绝对风险较低。
  • 仅28%的育龄糖尿病女性有激素避孕申报,多数使用含雌激素口服避孕药。
  • 与宫内避孕相比,孕激素注射避孕与血栓栓塞风险升高相关(校正HR 4.69 [95% CI 2.51-8.77])。

核心结论

  • 使用激素避孕的1型或2型糖尿病女性血栓栓塞绝对风险较低。
  • 宫内与皮下埋植避孕药具是希望避免高血糖致畸效应、认真计划妊娠的糖尿病女性的优良选择。

研究设计与样本

  • 使用2002-2011年Clinformatics Data Mart数据,识别美国14-44岁、有糖尿病ICD-9-CM编码且有糖尿病药物或器械处方的女性。
  • 检查避孕申报,采用改良Cox回归比较使用激素避孕的糖尿病女性至血栓栓塞(静脉血栓、卒中或心肌梗死)的时间,控制年龄、吸烟、肥胖、高血压、高脂血症、糖尿病并发症和癌症史。
  • 排除女性分娩后3个月内的数据。

主要发现

  • 识别146,080例糖尿病女性,发生3,012例血栓栓塞事件。
  • 仅28%的育龄糖尿病女性有激素避孕申报,其中多数接受含雌激素口服避孕药。
  • 血栓栓塞发生率在使用避孕贴片者中最高(每1,000女性年16例),在使用宫内(每1,000女性年3.4例)和皮下(每163女性年0例)避孕者中最低。
  • 与使用宫内避孕相比,孕激素注射避孕与血栓栓塞风险升高相关(每1,000女性年12.5例;校正风险比4.69 [95% CI 2.51-8.77])。

临床怎么用

  • 作者认为,宫内与皮下埋植避孕药具是希望避免高血糖致畸效应、认真计划妊娠的糖尿病女性的优良选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate safety of hormonal contraception with regard to thromboembolic events in women with type 1 or 2 diabetes. RESEARCH DESIGN AND METHODS: We used data from 2002-2011 in Clinformatics Data Mart to identify women in the U.S., 14-44 years of age, with an ICD-9-CM code for diabetes and a prescription for a diabetic medication or device. We examined contraceptive claims and compared time to thromboembolism (venous thrombosis, stroke, or myocardial infarction) among women with diabetes dispensed hormonal contraception using a modification of Cox regression to control for age, smoking, obesity, hypertension, hyperlipidemia, diabetic complications, and history of cancer; we excluded data for 3 months after women gave birth. RESULTS: We identified 146,080 women with diabetes who experienced 3,012 thromboembolic events. Only 28% of reproductive-aged women with diabetes had any claims for hormonal contraception, with the majority receiving estrogen-containing oral contraceptives. Rates of thromboembolism were highest among women who used the contraceptive patch (16 per 1,000 woman-years) and lowest among women who used intrauterine (3.4 per 1,000 woman-years) and subdermal (0 per 163 woman-years) contraceptives. Compared with use of intrauterine contraception, progestin-only injectable contraception was associated with increased risk of thromboembolism (12.5 per 1,000 woman-years; adjusted hazard ratio 4.69 [95% CI 2.51-8.77]). CONCLUSIONS: The absolute risk of thromboembolism among women with type 1 or 2 diabetes using hormonal contraception is low. Highly effective, intrauterine and subdermal contraceptives are excellent options for women with diabetes who hope to avoid the teratogenic effects of hyperglycemia by carefully planning their pregnancies.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. O'Brien SH, Koch T, Vesely SK, et al. Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes. Diabetes Care. 2016. PMID: 27899496. doi:10.2337/dc16-1534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。